TITLE

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes

AUTHOR(S)
Riddle, Matthew; Pencek, Richard; Charenkavanich, Supoat; Lutz, Karen; Wilhelm, Ken; Porter, Lisa
PUB. DATE
September 2009
SOURCE
Diabetes Care;Sep2009, Vol. 32 Issue 9, p1577
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE -- To compare the efficacy and safety of adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin for patients with inadequately controlled type 2 diabetes. RESEARCH DESIGN AND METHODS -- In a 24-week open-label, multicenter study, 113 patients were randomly assigned 1:1 to addition of mealtime pramlintide (120 µg) or a titrated RAIA to basal insulin and prior oral antihyperglycemic drugs (OADs). At screening, patients were insulin naive or had been receiving <50 units/day basal insulin for <6 months. The basal insulin dosage was titrated from day 1, seeking fasting plasma glucose (FPG) ≥270 - <100 mg/dl. Pramlintide and an RAIA were initiated on day 1 and week 4, respectively. The proportion of patients achieving A1C ≤7.0% without weight gain or severe hypoglycemia at week 24 was the primary end point. RESULTS -- More pramlintide- than RAIA-treated patients achieved the primary end point (30 vs. 11%, P = 0.018) with a similar dose of basal insulin. Pramlintide and an RAIA yielded similar mean ± SEM values for FPG and A1C at 24 weeks (122 ± 7 vs. 123 ± 5 mg/dl and 7.2 ± 0.2 vs. 7.0 ± 0.1%, respectively) and similar least squares mean reductions from baseline to end point (-31 ± 6 vs. -34 ± 6 mg/dl and -1.1 ± 0.2 vs. -1.3 ± 0.2%, respectively). RAIAs but not pramlintide caused weight gain (+4.7 ± 0.7 vs. +0.0 ± 0.7 kg, P < 0.0001). Fewer patients reported mild to moderate hypoglycemia with pramlintide than with the RAIA (55 vs. 82%), but more patients reported nausea (21 vs. 0%). No severe hypoglycemia occurred in either group. CONCLUSIONS -- In patients taking basal insulin and OADs, premeal fixed-dose pramlintide improved glycemic control as effectively as titrated RAIAs. The pramlintide regimen sometimes caused nausea but no weight gain and less hypoglycemia.
ACCESSION #
44561605

 

Related Articles

  • A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs. Swinnen, Sanne G.; Dain, Marie-Paule; Aronson, Ronnie; Davies, Melanie; Gerstein, Hertzel C.; Pfeiffer, Andreas F.; Snoek, Frank J.; Devries, J. Hans; Hoekstra, Joost B.; Holleman, Frits // Diabetes Care;Jun2010, Vol. 33 Issue 6, p1176 

    OBJECTIVE -- To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C <7% without symptomatic hypoglycemia ≤3.1 mmol/l. RESEARCH DESIGN AND METHODS -- In this 24-week trial, 973 insulin-naive type 2 diabetic patients on stable oral...

  • Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? YKI-JÄRVINEN, HANNELE; KOTRONEN], ANNA // Diabetes Care;Aug2013 Supplement, Vol. 36 Issue S2, pS205 

    The article examines research papers on the use of premixed or prandial insulin treatment regimens in insulin-naive or previously insulin-treatment patients with type 2 diabetes. The authors also examine the advantage of using premixed and basal-bolus regimens with or without oral hypoglycemic...

  • Early Insulin Use in Type 2 Diabetes. Chiasson, Jean-Louis // Diabetes Care;Nov2009 Supplement, Vol. 32, pS270 

    The article explores the negative effects of early insulin therapy in type 2 diabetes. It notes that published literature has not proved the ability of early insulin therapy to reduce cardiovascular risk and provide protection against β-cell. It discusses the microvascular and macrovascular...

  • Insulin Myths and Facts.  // Clinical Diabetes;Winter2007, Vol. 25 Issue 1, p39 

    The article presents information on several myths and facts about insulin. The indication of using insulin as a failure of diabetes management is a myth. Diabetes is considered as an insulin problem not as many people think that it is a sugar problem. Weight gain could be experience by patients...

  • Where do conventional OADs stand. Sahay, Rakesh Kumar; Nagesh, V. Sri // Indian Journal of Endocrinology & Metabolism;Dec2012 Supplement, Vol. 16, pS252 

    The last two decades have witnessed unprecedented activity in the field of OADs with many new drugs becoming available. Concerns with OAD include cardiovascular safety, fear about hypoglycemia, weight gain etc. In this article we attempt to review OADs, sulfonylureas in particular, in the light...

  • Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Miyako Kishimoto // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;2013, Vol. 6, p187 

    Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged as a new class of antidiabetic that show favorable results in improving glycemic control with a minimal risk of hypoglycemia and weight gain. Teneligliptin, a novel DPP-4 inhibitor, exhibits a unique structure characterized by five...

  • News in brief….  // Reactions Weekly;9/24/2005, Issue 1070, p3 

    Reports on the effects of insulin detemir on patients with type 2 diabetes mellitus who require insulin therapy according to the results of a multinational study presented at the 41st annual meeting of the European Association for the Study of Diabetes in Athens, Greece. Glycosylated...

  • Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents. Bretzel, Reinhard G.; Eckhard, Michael; Landgraf, Wolfgang; Owens, David R.; Linn, Thomas // Diabetes Care;Nov2009 Supplement, Vol. 32, pS260 

    The article discusses a study called A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantus once daily or Lispro at mealtime in type 2 diabetic patients failing Oral treatment (APOLLO) trial. It notes that the study showed that a once daily basal insulin...

  • Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Hanaire-Broutin, Helene; Melki, Vincent; Bessiees-Lacombe, Sylvie; Tauber, Jean-Pierre; Hanaire-Broutin, H; Melki, V; Bessières-Lacombe, S; Tauber, J P // Diabetes Care;Sep2000, Vol. 23 Issue 9, p1232 

    Objective: To compare the efficacy of 2 intensified insulin regimens, continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI), by using the short-acting insulin analog lispro in type 1 diabetic patients.Research Design and Methods: A total of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics